Hydroxyurea

FIG. 4. Effect of the combination of hydroxyurea HyU ; with either GCV A ; or CDV B ; on HSV-2 progeny formation in Vero cells in a single-cycle virus yield reduction assay.

AIDS Rev 2002; 4 18. Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistant mutations in HIV-1 reverse transcriptase gene in therapy nave patients receiving stavudine plus didanosine combination therapy. STADI group. AIDS 1999; 13: 1705-9. Winters M, Coolley K, Girard Y, et al. A 6-basepair insert in the reverse transcriptase of HIV type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75. Larder B, Bloor S, Kemp S, et al. A family of insertion mutations between codon 67 and 70 of HIV type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43: 1961-7. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of HIV type 1 variants with insertions and deletions in the reverse transcriptase RT ; : multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001; 45: 1836-42. Lin P, Rose R, Samanta H, et al. Genotypic and phenotypic analysis of HIV type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-64. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997; 11: 696-7. Lin PF, Gonzlez C, Griffith B, et al. Stavudine resistance: An update on susceptibility following prolonged therapy. Antiviral Ther 1999; 4: 21-8. Coakley E, Gillis J, Hammer S, et al. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14: 9-15. De Mendoza C, Soriano V, Briones C, et al. Emergence of zidovudine resistance in HIV-1 infected patients receiving stavudine. J AIDS 2000; 23: 279-81. Pozniak A, Gilleece Y, Nelson M, et al. Zidovudine genotypic and phenotypic resistance arising in patients never exposed to zidovudine. Antiviral Ther 2000; 5 Suppl 3 ; : 42. 28. Calvez V, Mouroux M, Descamps D, et al. Occurrence of thymidine-associated mutations in nave patients treated more than 6 months by stavudine lamivudine bitherapy combination and tritherapies including stavudine didanosine or stavudine: lamivudine. Antiviral Ther 2000; 5 Suppl 3 ; : 40-1. 29. Moyle G, Gazzard B. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine didanosine and stavudine lamivudine. AIDS 2001; 15: 799-800. Pellegrin I, Garrigue I, Caumont A, et al. Persistence of zidovudine-resistant mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen. AIDS 2001; 15: 1071-3. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine nave patients experiencing viremia on stavudine containing regimen. AIDS Res Hum Retrovir 2001; 17: 1107-15. Katlama C, Valantin M, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-nave and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1998; 129: 525-31. Izopet J, Bicart-See A, Pasquier C, et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999; 59: 507-11. Montaner J, Mo T, Raboud J, et al. HIV-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. J Infect Dis 2000; 181: 729-32. Shulman N, Machekano R, Shafer R, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J AIDS 2001; 27: 377-80. Demeter L , Nawaz T, Morse G, et al. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis 1995; 172: 1480-5. Shafer R, Winters M, Jellinger R, Merigan T. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis 1996; 174: 448-9. Winters M, Shafer R, Jellinger R, et al. HIV reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41: 757-62. Resistance mutations project panel. International AIDS Society-USA Resistance Testing Guidelines Panel. Update on Drug Resistance Mutations in HIV-1. Topics in HIV Medicine 2001; 9: 91-3. Meyer P, Matsuura S, So A, Scott W. Unblocking of chain terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 13471-6. Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of HIV type 1 selected during therapy. J Virol 1994; 68: 1660-6. Byrnes V, Sardana V, Schleif W, et al. Comprehensive mutant enzyme and viral variant assessment of HIV type 1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob Agents Chemother 1993; 37: 1576-9. Richman D, Shih C, Lowy I, et al. HIV type 1 mutants resistant to NNRTI arise in tissue culture. Proc Natl Acad Sci USA 1991; 88: 11241-5. Demeter L, Meehan P, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 136-44. Montaner J, Reiss P, Cooper D, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998; 279: 930-7. Staszewski S, Morales-Ramrez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73. Murphy R, Katlama C, Johnson V, et al. The Atlantic Study: A randomized open-label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. 39th ICAAC. San Francisco 1999 [abstract LB-22]. 48. Albrecht M, Bosch R, Hammer S, et al. Nelfinavir, efavirenz or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2000; 345: 398-407. Larder B. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring HIV type 1 resistance to NNRTI. Antimicrob Agents Chemother 1992; 36: 2664-9. Whitcomb J, Deeks S, Huang W, et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1 infected patients. 7th CROI. San Francisco 2000 [abstract 234]. 51. Haubrich R, Whithcomb J, Keiser P, et al. NNRTI viral hypersensitivity is common and improves short term virological response. 4th International Workshop on HIV Drug Resistance and Treatment Strategies. Sitges, Spain, 2000 [abstract 87]. 52. Shulman N, Zolopa A, Passaro D, et al. Phenotypic hypersusceptibility to NNRTI in treatment-experienced HIV-infected patients: impact on virological response to efavirenz based therapy. AIDS 2001; 15: 1125-32. Mellors J, Vaida F, Bennett K, et al. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398. 9th CROI. Seattle. February 24-28, 2002 [abstract 45]. 54. Frater A, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15: 1493-502. Descamps D, Collin G, Letourneur F, et al. Susceptibility of HIV type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71: 8893-8. Cox S, Aperia K, Albert J, et al. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 10: 1725-9. Tomasselli A, Hui J, Sawyer T, et al. Specificity and inhibition of proteases from HIV 1 and 2. J Biol Chem 1990; 265: 14675-83.

Neck or a stellate ganglion block. Cirrhosis and uremia also produce some degree of nasal congestion. Idiopathic rhinitis Unfortunately, some patients with either nasal congestion or rhinorrhea defy diagnosis despite thorough investigation. Empiric therapeutic trials are then offered with topical ipratropium, atropine, or cromolyn and with nonspecific measured discussed below. Diagnosis History taking requires an awareness not only about nasal disorders per se, but also about systemic disorders with nasal manifestations, as noted in the previous list and box also see Chapter 40 ; . Vasomotor rhinitis is often a diagnosis of exclusion, and necessarily so because other causes of nasal obstruction are far more prevalent. Allergic rhinitis is the most common cause of chronic nasal congestion; the common cold predominates as the most frequent cause of acute complaints. The patient's history is vital. A thorough examination of the nasal passages including the nasopharynx ; before and after application of a topical nasal decongestant may reveal the diagnosis. When nasal examination shows only boggy, swollen membranes of the inferior turbinates as in Fig. 45-3 ; , it is a nonspecific finding. The nasal membrane congestion of allergy and infection is a pathophysiologic response that is indistinguishable from the vasomotor phenomenon of pregnancy, of nose spray abuse, or of hypothyroidism. Various authors from time to time have implied that certain colorations of the mucosa suggest certain specific disorders. In practice, however, such color variations are usually too subtle to be of much help. The nature of the secretions is more helpful: yellow pus suggests bacterial infection; bloody crusty secretions and ulcerations suggest bacterial infections, neoplasm, or granulomatous disease; clear secretions suggest either allergy or viral infection; and nasal smears with large numbers of eosinophils suggest allergy - as opposed to neutrophils which suggest infection. The response of the nasal membranes to topical nose spray ; vasoconstriction helps to differentiate a vasomotor rhinitis which should show a considerable decongestive response ; from structural deformities, neoplasms, polyps, sarcoidosis, or the bony turbinate overgrowth of compensatory hypertrophy - all of which should show a limited response. Additionally, many patients with long-established nose spray abuse will demonstrate little vasoconstrictive response to the nose spray used during the examination. Sarcoidosis Fig. 45-6 ; , granulomatous disorders, polyps, and tumors are identified by tissue biopsy. Sinus x-ray films are useful not only to detect sinus infections, but also to 9. Cells were incubated for 2 h, and then DMEM with 10 % or 5 % FBS and dexamethasone 1 mol L were added to wells respectively. At d 2 cells were collected and carried out for luciferase activity assay. Drug treatment Hydroxyurea and etoposide were diluted into DMEM with various concentrations for use in experiments. The concentrations of hydroxyurea were 0.2-200 mmol L and etoposide were 0.0550 mol L, which were adequate to inhibit DNA synthesis[13]. Drug treatments were the 12-14 h overnight incubations. After treatment, cultures were washed twice with DMEM, then AAV vectors were added for transduction, and the cultures were maintained in DMEM containing 10 % FBS dividing culture ; or DMEM containing 5 % FBS and dexamethasone 1 mol L stationary culture ; . Luciferase activity assay Two days after transduction, luciferase activity assay were performed. Cells were washed twice with PBS, and then 300 L luciferase lysis buffer was added to the wells. After 15 min at room temperature, cells were collected to centrifuge tube and centrifuged at 2000g for 15 s. According to the Promega assay system, 20 L supernatant and 100 L reagent buffer were mixed, then relative light unites per second RLU s ; was detected immediately by luminometer. The RLU s of untreated hMSCs was regarded as base, and the transduction efficiency was indirectly reflected by counting the relative values of luciferase activity in various groups. The relative transduction efficiency was the number of RLU s in drug treated cultures divided by the number in untreated cultures. The bigger the RLU s, the higher the transduction efficiency. Southern blot Stationary cells were treated with hydroxyurea of 0, 0.2, 20 mmol L and etoposide of 0, 0.05, 3 mol L, respectively. Then cells were transducted by rAAV-LUC at a MOI of 1105 vector particles per cell as described above. Two days after transduction, cells were collected and counted. Lowmolecular-weight genomic DNA was isolated by the method of Hirt[17]. Cells 1107 were lysed by 1 mL 0.6 % sodium dodecyl sulphate-Tris-hydrochloride 10 mmol L ; -edetic acid 10 mmol L, pH 7.4 ; . After 20 min at room temperature the viscous lysate were harvested into centrifuge tube. Then 0.25 mL NaCl 5 mmol L was added to make a final concentration of 1 mmol L, and the solution was gentlely mixed by inverting the tube 10 times. Then the tube was left on ice for 1 h. The sample was mixed again and kept at 4 C and indinavir. 26. Lavender, S., and McGill, R. J., Nonketotic hyperosmolar coma and frusemide therapy. Diabetes 23, 247 1974 ; . 27. Redetzki, H. M., et al., Differences between serum and plasma osmolalities and their relationship to lactic acid values. Proc. Soc. Exp. Biol. Med. 139, 315 1972 ; . 28. Ross, E. J., and. This iesearch was supported by the Natlonal Reaearch Council of Canada. Contiact A 1764 and the United States 4tomic Eneigy Commission, Contract A T 45 1914 Genetics 51 : 6 April 1965 and infliximab!

Blood and marrow samples were diluted with tissue culture medium Iscove's modified Dulbecco's medium, IMDM ; , layered over Ficoll-Hypaque Pharmacia, Piscataway, NJ ; and centrifuged for 20 minutes at 2, 200 rpm at 18# C. cells at the The interface were collected, washed, and plated at 1 to cells mL in 35-mm Petri dishes Falcon ; in a mixture containing 0.9% methylcellulose, 30% fetal calf serum FCS, Gibco, Grand Island, NY ; , 9.0 mg mL deionized bovine serum albumin BSA, Sigma, St Louis, fraction V ; , 1.4 x 10 mol L fl-mercaptoethanol, 5% Mo cell line-conditioned medium as a source of BPA generously provided by Dr David Golde ; and with 2.0 U mL crude erythropoietin Toyobo ; in IMDM. The plates were incubated in humidified 4% CO2 at 37# C 7 and 14 days. for The frequency of bone marrow CFU-E 7-day culture ; and BFU-E 14-day culture ; and of peripheral blood BFU-E-derived colonies I x I cells was assessed in patients who had been treated in vivo with hydroxyurea. The number of cells per erythroid colony, the picograms of fetal and total hemoglobin, and the percentage of fetal hemoglobin per progenitor-derived cell were also measured. Approximately 50 to 100 progenitor-derived colonies were plucked per sample, an aliquot was counted, and the average number of erythroid cells per colony was determined. When samples were plucked in duplicate or triplicate, the mean number of cells per colony 1 SD was determined. Statistical significance of changes noted following treatment was determined with Student's paired test. Hydroxyurea Squibb, Princeton, NJ, 97.6% pure ; was added to erythroid culture dishes on days 3 through 13 following initiation of cultures derived from normal controls, AS controls, patients with SCA, and two monkeys. The drug was brought to a final concentration ofO to 100 tmob L, added at only one time point per dish, and was allowed to remain in the dish until completion of the 14 days of. FIG. 2. Coupled T7 RNA polymerase promoter system. The construction of plasmid pGPl-2 A ; , which expressed T7 RNA polymerase, has been previously published Tabor and Richardson, 1985 ; . It contains a T7 RNA polymerase gene T7 gene I ; , the X repressor gene cI&, the kanamycin resistance gene Kan' ; , and the P15A origin of replication. Cells also contain a second plasmid, compatible with the first, which was derived from PET-3 Studier et al., 1990 ; . The parent plasmid contains the P-lactamase gene for ampicillin resistance, the ColEl origin of replication, the T7 transcriptional promoter from the T7 gene 10 &JO ; , a T7 transcriptional terminator T4 ; , and a single BamHI cloning site between 410 and Tb. The gene for wild-type ribosomal protein L2 rplB ; was cloned into the unique BamHI site to generate pPRlOO1 B ; . The 1.3 kilobase kb ; SmaISal1 fragment from this plasmid was cloned into M13mpll for sitedirected mutagenesis of rplB as described under "Materials and Methods." The modified sequences were subsequently cloned back into the expression vector to generate a series of plasmids designed for the overproduction of mutant L2 protein see Fig. 1 and Table I ; . Protein Composition of 40 S Particles from Cells Overproducing L2: A222-228-The 50 S and 40 S peak fractions from and invirase. 109 ; Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, revalo-Herrera M et al. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. J Trop Med Hyg 2005; 73 5 Suppl ; : 10-15. Instituto de Inmunologia, Universidad del Valle, Cali, Colombia. PubMed 110 ; Joseph A, Mony P, Prasad M, John S, Srikanth, Mathai D. The efficacies of affected-limb care with penicillin diethylcarbamazine, the combination of both drugs or antibiotic ointment, in the prevention of acute adenolymphangitis during bancroftian filariasis. Ann Trop Med Parasitol 2004; 98 7 ; : 685-696. Department of Community Health, Christian Medical College, Vellore, India. PubMed.
In BHK-21 cells treated with caffeine after isoleucine depletion and prolonged hydroxyurea blockade, and after less continuous hydroxyurea treatment: a ; frequencies of S-phase condensed figures in cells given caffeine after isoleucine depletion hydroxyurea synchrony open circles ; , and in cells given 2 mM hydroxyurea when in random proliferating culture open squares b ; frequencies of S-phase condensed figures open symbols ; and mitotic figures solid symbols ; in cells given caffeine after isoleucine depletion hydroxyurea synchrony open circles ; , and in cells released from hydroxyurea arrest for 2 h and then given caffeine with hydroxyurea open squares ; or 2 mM caffeine with 0.05 ~g ml colcemid open.

It is not clear whether the poly ADP-ribosyl ; ation of nuclear proteins is affected by synchronizing agents during the cell synchronization. In our present experiments, the nuclei isolated from the cells which were pretreated with thymidine showed a significantly increased activity of poly ADP-ribosyl ; ation. The increased activity induced by in vivo treatment was also observed with nicotinamide but not with hydroxyurea and amethopterin. These observations indicate that thymidine as well as nicotinamide affect the properties of HeLa S3 cell nuclei in vivo so as to allow increase in the activity of poly ADP-ribosyl ; ation in isolated nuclei. As mentioned in our previous report ll ; , the activity of poly ADP-ribosyl ; ation in isolated nuclei measured under optimal conditions for poly ADP-ribose ; synthesis is determined by three parameters: i ; amount of poly ADP-ribose ; polymerase, ii ; number of acceptor proteins or acceptor sites, and iii ; state of nuclear structure. A possibility of the increase in activity in the first parameter, amount of poly ADP-ribose ; polymerase, was excluded by the result shown in Table II. The increase observed by the treatment with thymidine seems to be independent of the inhibitory effect of DNA synthesis because little increase in the activity was noted on treatment with hydroxyurea or amethopterin. Considering the fact that all these synchronizing agents affect DNA synthesis by the inhibition of precursor synthesis, it is unlikely that there is significant difference among these agents in the third param.